Cognition therapeutics jobs


Work at Cognition Therapeutics? Share your experience anonymously. Zippia's Best Places to Work lists provide unbiased, data-based evaluations of companies. Rankings are based on government and proprietary data on salaries, company financial health, and employee diversity.


We are searching data for your request:

Cognition therapeutics jobs

Employee Feedback Database:
Leadership data:
Data of the Unified State Register of Legal Entities:
Wait the end of the search in all databases.
Upon completion, a link will appear to access the found materials.
Content:
WATCH RELATED VIDEO: How Does Cognitive Behavioral Therapy Work?

Cognition Therapeutics, a Pittsburgh Life Sciences Greenhouse portfolio company, goes public


It embodies our mission to protect cognitive function in patients with our first-in-class therapeutics that target microglia and halt neurodegeneration. Tiaki has identified a transcriptomic signature of neuroinflammation in dementia patients that can be used to nominate targets for drug development.

These targets from patients have been validated in our proprietary discovery engine that models the conserved biology of neuroinflammation. Our differentiated approach leverages this conserved biology to drive the development of novel therapeutic targets and biomarkers in patients with multiple neurodegenerative diseases.

To transform the lives of patients and their families affected by dementia by delivering disease-modifying therapies. At Tiaki, we are passionate about the potential of our approach and our first focus is identifying treatments for neurodegenerative diseases. Neurodegenerative diseases affect millions of people.

Other neurodegenerative diseases are more rare, but all have devastating consequences. Next generation bioinformatics can now analyze genomics, transcriptomics, and other patient data to reveal new insights for drug development.

Targeting microglia is a new therapeutic approach, focused on neuroinflammation pathways that drive cognitive decline. Microglia , the immune cells of the brain, play a critical role in neuroinflammation.

Microglia normally function in concert with other cells in the brain to drive important processes that maintain CNS health. Dysregulation of microglia cellular interactions and functions play a key role in disease processes. Mutations in genes expressed by microglia are associated with increased risk for developing dementia.

Our approach targeting microglia represents a promising new therapeutic strategy. Chronic neuroinflammation is a hallmark of many neurodegenerative diseases and this conserved biology of the innate immune system has been linked to cognitive decline.

Neuroinflammation is the result of dysregulation of inflammatory cell function in the brain. Genetic data links altered function in microglia with uncontrolled neuroinflammation. Left unchecked, chronic inflammation is detrimental to neuronal health and function.

There, she successfully negotiated an exclusive agreement with Bristol Myers Squibb for the right to acquire Promedior. Prior to Promedior, she spent 13 years at Shire Human Genetic Therapies HGT , a division of Shire PLC, where she held a series of positions of increasing responsibility before serving as senior vice president of strategic planning and program management. Bruhn was responsible for establishing the program management function, driving strategic planning and portfolio management, and for global regulatory affairs.

Prior to her time at HGT, Dr. Bruhn held various positions at Cytotherapeutics, Inc. Bruhn currently sits on the board of directors of Aeglea BioTherapeutics, Inc. Most recently, Dr. Miller held the role of head of discovery chemistry at Shire, where he built and oversaw all key aspects of small molecule drug discovery for rare diseases and other unmet medical needs.

Prior to that he held positions of increasing responsibility during a year tenure at Merck, where he led drug discovery teams, development teams, and provided strategic leadership and oversight to licensing, collaboration and global business initiatives. He has contributed to more than scientific publications and patents. He previously served as the VP of preclinical research and development at Proclara, where he oversaw two preclinical programs characterizing novel biological therapeutics targeting misfolded proteins in neurodegenerative, orphan and metabolic disease.

Prior to joining Proclara, he worked at Galenea, a drug development company focusing on the cognitive symptoms of psychiatric disorders, where he held positions of increasing responsibility, culminating in the role of senior scientist. Before that, Dr. Levenson was an assistant professor and the director of the rodent behavioral core at the University of Wisconsin-Madison.

He was previously a consultant at Saegis Pharmaceuticals and an assistant professor at Baylor College of Medicine. Levenson earned his Bachelor of Science, cum laude, from Vanderbilt University, his doctorate in Biology from the University of Houston, and was a postdoctoral fellow at the Baylor College of Medicine.

He has authored or co-authored over 60 research publications focused on neuropharmacology and the treatment of neurological diseases. Her doctoral work was performed at the Gladstone Institutes at UCSF where, as part of an academic consortium funded by the nonprofit Bluefield Project, she worked to elucidate the CNS function of progranulin and its causal role in frontotemporal dementia. She has authored or co-authored 20 research publications focused on microglial biology and mechanisms of neurodegenerative diseases.

Angus returned to the Summit NJ Headquarters as VP, Business Development and Global Alliances, in , where he built the alliance management function to manage over 60 collaborations and completed multiple innovative deals.

In , Angus became focused on deals, serving as Corporate VP of Business Development, leading a BD team running the transactions from deal inception to close as well as select acquisitions before leaving Celgene for the DDF. Angus received his undergraduate degree from the University of Richmond, then his Ph.

Jon joined the DDF as Partner in July of , and brings over 10 years of venture and venture creation experience. His areas of responsibility included neuroscience, and successes included Tilos Therapeutics.

In these roles he co-founded and supported seven companies and took senior operating roles in several. Jon has a Ph. She is trained as a neuroscientist who has worked in both large and small pharmaceutical companies. Tiaki Therapeutics presents data on identification of a novel target for neuroinflammatory-driven neurodegenerative disease validated by its systems biology platform.

Tiaki Therapeutics announces plans to collaborate with Eisai to evaluate novel therapeutics for neuroinflammatory diseases. Development of a neuroinflammatory systems biology platform to enable drug discovery for disease-modifying therapeutics for neurodegenerative disease. We are a team of passionate drug developers who are unafraid to blaze a new trail in diseases that need new science and new approaches.

If you are interested in joining our team, please consider the open positions below, and check back with us we continue to grow. About Tiaki Tiaki has identified a transcriptomic signature of neuroinflammation in dementia patients that can be used to nominate targets for drug development. Our Vision To transform the lives of patients and their families affected by dementia by delivering disease-modifying therapies.

Major Diseases of Our Time Neurodegenerative diseases affect millions of people. Insights from Patient Data Next generation bioinformatics can now analyze genomics, transcriptomics, and other patient data to reveal new insights for drug development.

New Therapeutic Solution Targeting microglia is a new therapeutic approach, focused on neuroinflammation pathways that drive cognitive decline. Tiaki ex vivo Systems Biology. Curated Human Datasets. Bioinformatics Analysis. These insights have identified druggable targets that reverse the neuroinflammatory signatures, and, in parallel, reveal biomarkers that can be used to speed drug development. Neuroinflammation in neurodegenerative diseases Chronic neuroinflammation is a hallmark of many neurodegenerative diseases and this conserved biology of the innate immune system has been linked to cognitive decline.

Neuroinflammation is a critical driver of cognitive decline in dementia. Chronic inflammation is detrimental to neuronal health and function. Genetic data links altered function of microglia with neuroinflammation. Time for a different approach targeting neuroinflammation to open up new possibilities for treatment. Neuroinflammatory signature identified by Tiaki reveals a specific set of genes dysregulated in patients. Activated microglia are key contributors to neurotoxicity and synapse loss.

Management Board of Directors. Suzanne Bruhn, PhD. Angus Grant, PhD. Oct 21, Tiaki Therapeutics presents data on identification of a novel target for neuroinflammatory-driven neurodegenerative disease validated by its systems biology platform Jul 10, Tiaki Therapeutics appoints Suzanne Bruhn, PhD, as Chief Executive Officer Mar 29, Tiaki Therapeutics announces plans to collaborate with Eisai to evaluate novel therapeutics for neuroinflammatory diseases.

Tiaki Poster Presentation at Neuroscience , October , Development of a neuroinflammatory systems biology platform to enable drug discovery for disease-modifying therapeutics for neurodegenerative disease. Open Positions There are no open positions at this time. Tiaki Therapeutics Inc. All rights reserved.



Investor Overview

We'll help them live their lives at their best—that's a promise. We see opportunities to improve health through nutrition everywhere. Our expertise areas are rooted in science and cover every facet of health: prevention, maintenance, and treatment. We have a wide range of brands that use the power of nutrition to help people live their healthiest lives, supporting every life stage from pediatrics to healthy aging. From newborn babies to the most senior citizens, we provide nutrition and nourishment where it's needed most. We are a global group of people who share a passion for empowering healthier lives through nutrition. The difference that we make for consumers, patients, and caregivers is what motivates us.

Dr. Hank Safferstein, CEO, Cognition Therapeutics, Inc. – Dr. Bernardo Cordovez, Ph.D., Co-founder & CEO, Optofluidics.

Ginger therapist salary

Linus Health seeks to radically improve brain health outcomes for people everywhere by transforming the way we measure, monitor, and maintain brain function. Starting with better brain health assessments, we are leveraging advancements in neuroscience technology, machine learning, and human expertise to enable precision brain health. Our brains contain nearly billion neurons and trillion synapses. This complexity poses a significant challenge to deciphering brain function and assessing or quantifying brain health. No single metric or measure can provide a complete picture, and current methods—while powerful—are time-consuming, invasive, and prohibitively expensive. The Linus platform uses everyday mobile technology to deliver meaningful insights more quickly and affordably than current gold-standard assessments. Our multimodal approach is built on an array of scientifically validated tools and cross-validation metrics to provide a constellation of digital biomarkers and enable a more holistic assessment of neurocognitive health.


Psychiatry

cognition therapeutics jobs

Winterlight has developed a tablet-based assessment that is fast, objective, and stress-free. By analyzing speech alone, we can detect cognitive impairment associated with dementia and mental illness. Our assessment can be used in life science research, senior care and clinical settings. Trusted by five of the top ten Life Sciences companies to measure disease progression and response to therapy.

Cambridge Cognition is pleased to announce the completion of the spin-out of Monument Therapeutics, a drug development company applying digital phenotyping to central nervous system CNS disorders.

cognition therapeutics Jobs in purchase,ny - 48

Many seniors enjoy reading in their free time, and some even set aside time every day for this activity. However, they likely read for sheer pleasure without even realizing how healthy it is for them to curl up with a good book on a regular basis. Oakville, ON, home care experts discuss a few of the many advantages for seniors who consider themselves avid readers. A study conducted by the University of Sussex concluded a mere 6 minutes of reading could reduce stress by up to 68 percent. Lower stress levels can decrease the risk of obesity and hypertension, relax tense muscles, and lower the perception of pain due to chronic illnesses.


Drug Discovery & Development Support Services (DDDSS)

Neurotrack develops digital cognitive health solutions that enable people to assess, monitor and strengthen their brain health to reduce the risk of Alzheimer's and other dementias. Our solutions are built on a digital platform, enabling convenient and remote cognitive testing from the privacy of home. Our products are available to businesses, researchers, and health organizations to provide to individuals. Learn and incorporate targeted behaviors, like building quality sleep or brain training, that are clinically-proven to benefit cognitive health. Our team of neuroscientists, neuropsychologists, and data scientists deliver the latest preventative advice, technologies and data-based science, all in the name of preserving cognition and reducing the risk of Alzheimer's. Neurotrack Menu. Keep your mind sharp and memory intact.

I currently head the Cognitive Therapeutics Research Program at MAPrc [Monash Alfred Psychiatry Research Centre], having been promoted to.

Assistant Professor in Language Data Analytics and Computational Linguistics

Our goal is to develop disease modifying treatments for patients with these degenerative disorders by initially leveraging our expertise in the sigma-2 s-2 receptor, which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. We believe that targeting the s-2 receptor complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, are forward-looking statements.


Zheng lab ucla

RELATED VIDEO: Cognitive Automation – bots liberating employees and reimagining jobs

To participate, please find a trial that is right for you or someone you love and contact a clinical site near you. Each of our studies have different eligibility criteria. While not everyone can join a trial, you can always become an advocate by sharing the trials with someone you know who might be able to participate. To watch an informational video about why your participation in clinical trials is so important, click here. AHEAD Study combines two studies with distinct participant groups but with common screening and recruitment to increase efficiency. More details on each study can be found on the study website.

Try out PMC Labs and tell us what you think.

Through these efforts, we aim to create shareholder value and advance medicines for Alzheimer's and other neurodegenerative diseases. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy.

One of the aims of the Brain Innovation Days is to create matchmaking and networking opportunities for all members of the brain community, facilitate business opportunities and value creation. We want to provide a platform for dialogue, knowledge-sharing and facilitate synergies across a wide range of sectors, including PhD and post-doc positions, administration, communications, IT, project management and more, within the brain ecosystem in Europe and beyond. In , more than million people worldwide were estimated to suffer from brain disorders, imposing an economic burden of nearly billion EUR in patient care. Therefore, the urgent need of the hour is to identify creative interventions to heal the brain and cure the mind.


Comments: 2
Thanks! Your comment will appear after verification.
Add a comment

  1. Washburne

    I have eliminated the problem

  2. Kamarre

    did you have a headache today?

+